53141Testing of a digitised process of healthcare patients waiting for treatment.ClosedStudyInnovate UKIn Scotland alone, data indicates that NHS theatre lists for operations are running at below 60% of capacity due to a number of factors but primarily because of the widespread use of manual systems for input through paper-based and electronic spreadsheets. Infix is a clinician-led, cloud-enabled technology platform targeting significant improvements in theatre efficiency in the NHS. Incorporating high levels of security and privacy, Infix aims to automate and harmonise existing NHS legacy systems within the NHS with an intuitive digital interface that can be accessed by a single, secure web-based access portal. Internal forecasts indicate that operating theatre efficiency could be increased by up to 50% - saving the NHS hundreds of millions of pounds per annum, reducing the reliance on the private sector, improving low levels of morale in the NHS and, most importantly, saving lives. The NHS is facing financially unsustainable positions and, to make matters worse, Covid-19 is only going to exacerbate the situation and add even greater complexity. Overall and most alarmingly, the upshot is that patients face worsening health conditions and increased mortality rates because of an out-of-date system that requires a radical overhaul. We have developed a product to optimise the NHS's own data in order to make theatre scheduling vastly more efficient. We will do this with a technology platform which integrates with existing NHS systems and completely automates the generation of theatre lists. Infix will also allow other systems to link into our product such as bed capacity software, equipment tracking software, resource management systems and pre-operative assessment tools. Utilising artificial intelligence, machine learning and the cloud, Infix will bring about a new level of consistency across the NHS, facilitating knowledge sharing, nationwide benchmarking and the production of much more actionable data. The Infix team sees particular demand for its product as the United Kingdom moves through various phases of the coronavirus pandemic and the ensuing and exacerbated waiting list backlog, and all the related financial and social costs that will result. While the focus of our first phase of development and growth concentrates on NHS Scotland, we see the application extending to NHS England, the rest of the UK and, further down the line, export potential in terms of take-up in international healthcare markets.